Last reviewed · How we verify

NCT02862977

Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment

Completed Phase 3 Last updated 2 April 2020
What this trial tests

Phase 3 trial testing ketoprofen and cyclobenzaprine association with caffeine in Musculoskeletal Pain in 414 participants. Completed in 20 December 2019.

Timeline
10 November 2017
Primary endpoint
5 June 2019
20 December 2019

Quick facts

Lead sponsorEMS
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment414
Start date10 November 2017
Primary completion5 June 2019
Estimated completion20 December 2019
Sites6 locations across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

EMS — full company profile →

Who can join

Adults 18 to 65, any sex, with Musculoskeletal Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of an association with one anti-inflammatory and one muscle relaxant plus caffeine compared to one anti-inflammatory plus caffeine in the treatment of osteomuscular pain in adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
    Jones P, Lamdin R, Dalziel SR. · · 2020 · cited 17× · PMID 32797734 · DOI 10.1002/14651858.cd007789.pub3

Verify or expand the search:

Other recruiting trials for Musculoskeletal Pain

Currently open trials in the same condition.

Other EMS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02862977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing